Sinopharm Group Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Sinopharm Group ha aumentado sus beneficios a una tasa media anual de 9.3%, mientras que los beneficios de la industria de Healthcare han experimentado un crecimiento de 4.8% anual. Los ingresos han ido creciendo a una tasa media de 10.3% al año. La rentabilidad financiera de Sinopharm Group es de 12.5%, y sus márgenes netos son de 1.5%.

Información clave

9.3%

Tasa de crecimiento de los beneficios

8.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	11.3%
Tasa de crecimiento de los ingresos	10.3%
Rentabilidad financiera	12.5%
Margen neto	1.5%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05

You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend

Feb 18

Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?

Feb 03

Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?

Jan 19

At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?

Jan 06

What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?

Dec 25

Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares

Dec 15

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Dec 04

Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years

Nov 25

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Sinopharm Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:1099 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	596,570	9,054	26,775	0
30 Sep 23	591,686	8,765	26,639	50
30 Jun 23	591,626	8,936	26,657	0
31 Mar 23	570,067	8,688	25,995	34
31 Dec 22	552,148	8,526	25,346	0
30 Sep 22	546,147	7,914	24,584	84
30 Jun 22	533,403	7,870	24,276	0
31 Mar 22	528,383	7,970	23,884	19
31 Dec 21	521,051	7,759	23,656	0
30 Sep 21	510,091	7,930	24,049	29
30 Jun 21	501,770	7,874	23,652	0
31 Mar 21	482,281	7,591	22,942	15
31 Dec 20	456,415	7,187	21,873	0
30 Sep 20	440,194	6,615	21,135	0
30 Jun 20	427,372	6,174	20,430	0
31 Mar 20	424,494	5,918	20,144	-5
31 Dec 19	425,273	6,251	19,797	0
30 Sep 19	406,394	6,311	18,856	22
30 Jun 19	382,717	6,012	18,128	0
31 Mar 19	360,760	6,087	16,903	11
31 Dec 18	344,526	5,834	16,235	0
30 Sep 18	336,113	5,523	15,420	75
30 Jun 18	334,060	5,606	15,580	0
31 Mar 18	318,414	5,083	14,416	22
31 Dec 17	308,354	5,572	13,353	0
30 Sep 17	288,855	5,217	12,094	0
30 Jun 17	269,356	4,861	10,836	0
31 Mar 17	264,691	4,996	10,875	0
31 Dec 16	258,388	4,635	10,744	0
30 Sep 16	251,401	4,515	10,512	0
30 Jun 16	244,414	4,394	10,279	0
31 Mar 16	234,499	3,885	9,964	0
31 Dec 15	228,673	3,772	9,755	0
30 Sep 15	222,513	3,548	9,504	0
30 Jun 15	216,353	3,323	9,254	0
31 Mar 15	207,865	3,037	8,890	0
31 Dec 14	200,131	2,875	8,681	0
30 Sep 14	190,883	2,719	8,447	0
30 Jun 14	181,635	2,564	8,212	0
31 Mar 14	174,251	2,407	7,899	0
31 Dec 13	166,866	2,250	7,586	0
30 Sep 13	158,436	2,211	7,176	0
30 Jun 13	150,006	2,172	6,767	0

Ingresos de calidad: 1099 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(1.5%) de 1099 son inferiores a los del año pasado (1.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 1099 han crecido un 9.3% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 1099 en el último año (6.2%) está por debajo de su media de 5 años (9.3% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 1099 en el último año (6.2%) no superó al de la industria Healthcare 13.4%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 1099 (12.5%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sinopharm Group Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022)

Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Sinopharm Group (HKG:1099) A Risky Investment?

Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Dividend of CN¥0.87 announced

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Investor sentiment improves as stock rises 16%

Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022)

Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

New major risk - Financial position

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023

Upcoming dividend of CN¥0.82 per share at 3.4% yield

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Sinopharm Group Co. Ltd. Approves Board Appointments

Is Sinopharm Group (HKG:1099) A Risky Investment?

Third quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report Q3, 2022 Results on Oct 26, 2022

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Second quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Now 20% undervalued

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Now 20% undervalued

Sinopharm Group Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable No Later Than 23 August 2022

Upcoming dividend of CN¥0.75 per share

Sinopharm Group Co. Ltd. Announces Executive Changes

Sinopharm Group Co. Ltd. Announces Resignation of Deng Jindong as Member of Audit Committee and Remuneration Committee of Board

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Sinopharm Group Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 23 August 2022

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Sinopharm Group Co. Ltd. to Report Q1, 2022 Results on Apr 21, 2022

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Sinopharm Group Co. Ltd., Annual General Meeting, Jun 23, 2022

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Now 22% undervalued

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Third quarter 2021 earnings released: EPS CN¥0.68 (vs CN¥0.75 in 3Q 2020)

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Independent Chief Supervisor Yifang Wu has left the company

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Boyu, Sinopharm Reportedly Among Bidders Shortlisted for Mundipharma China

Upcoming dividend of CN¥0.69 per share

Desglose de ingresos y gastos
Beta